Invasive Streptococcus pyogenes infection: a case report

Samia Bazhar1,2, Yassine ElBenaissi3, Elmostafa Benaissa1,2

  • 1Department of Clinical Bacteriology, Mohammed V Military Teaching Hospital, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.

Access Microbiology
|August 12, 2024
PubMed

Insights

Group A Streptococcus (GAS) can cause severe invasive infections. A 28-year-old patient recovered from septic arthritis caused by Streptococcus pyogenes after prompt diagnosis and treatment.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Clinical Medicine

Background:

  • Group A Streptococcus (GAS), or Streptococcus pyogenes, causes diverse infections, from mild pharyngitis to severe invasive diseases.
  • Despite antibiotic effectiveness, severe GAS infections have increased in industrialized nations since the 1980s.
  • GAS is a Gram-positive, beta-hemolytic bacterium naturally found in the human pharynx and skin, transmitted via respiratory droplets or skin contact.

Observation:

  • A 28-year-old patient presented with acute febrile oligoarthritis following flu-like symptoms and tonsillitis.
  • Clinical examination revealed swelling, positive patellar tap, and sternal involvement, with imaging showing a knee abscess and mediastinitis.
  • Emergency aspiration confirmed the presence of Streptococcus pyogenes, leading to a diagnosis of septic arthritis.

Findings:

  • The patient received dual antibiotic therapy and underwent knee joint drainage.
  • Symptoms resolved completely within 45 days of treatment.
  • This case highlights the potential for invasive GAS infections even in young, otherwise healthy individuals.

Implications:

  • The rising incidence of severe GAS infections necessitates enhanced early detection and prompt treatment strategies.
  • Disseminating antibiotic prophylaxis guidelines and fostering collaboration between clinicians and microbiologists are crucial for effective management.
  • This case underscores the importance of considering invasive GAS in patients presenting with severe joint or systemic symptoms.